1. Home
  2. MREO vs NQP Comparison

MREO vs NQP Comparison

Compare MREO & NQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • NQP
  • Stock Information
  • Founded
  • MREO 2015
  • NQP 1990
  • Country
  • MREO United Kingdom
  • NQP United States
  • Employees
  • MREO N/A
  • NQP N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • NQP Trusts Except Educational Religious and Charitable
  • Sector
  • MREO Health Care
  • NQP Finance
  • Exchange
  • MREO Nasdaq
  • NQP Nasdaq
  • Market Cap
  • MREO 424.5M
  • NQP 412.0M
  • IPO Year
  • MREO N/A
  • NQP N/A
  • Fundamental
  • Price
  • MREO $2.85
  • NQP $11.03
  • Analyst Decision
  • MREO Strong Buy
  • NQP
  • Analyst Count
  • MREO 7
  • NQP 0
  • Target Price
  • MREO $7.71
  • NQP N/A
  • AVG Volume (30 Days)
  • MREO 1.2M
  • NQP 58.4K
  • Earning Date
  • MREO 08-12-2025
  • NQP 01-01-0001
  • Dividend Yield
  • MREO N/A
  • NQP 3.21%
  • EPS Growth
  • MREO N/A
  • NQP N/A
  • EPS
  • MREO N/A
  • NQP N/A
  • Revenue
  • MREO N/A
  • NQP N/A
  • Revenue This Year
  • MREO N/A
  • NQP N/A
  • Revenue Next Year
  • MREO $54.07
  • NQP N/A
  • P/E Ratio
  • MREO N/A
  • NQP N/A
  • Revenue Growth
  • MREO N/A
  • NQP N/A
  • 52 Week Low
  • MREO $1.58
  • NQP $9.65
  • 52 Week High
  • MREO $5.02
  • NQP $11.89
  • Technical
  • Relative Strength Index (RSI)
  • MREO 64.74
  • NQP 45.09
  • Support Level
  • MREO $2.61
  • NQP $11.02
  • Resistance Level
  • MREO $2.85
  • NQP $11.20
  • Average True Range (ATR)
  • MREO 0.17
  • NQP 0.06
  • MACD
  • MREO 0.03
  • NQP -0.00
  • Stochastic Oscillator
  • MREO 88.83
  • NQP 23.91

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About NQP Nuveen Pennsylvania Quality Municipal Income Fund

Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: